Title
Carfilzomib-related acute kidney injury may be prevented by N-acetyl-L-cysteine
Publication Date
2014
Journal Title
J Oncol Pharm Pract
Abstract
Carfilzomib is a second-generation epoxyketone proteasome inhibitor that is approved for treatment of relapsed and refractory multiple myeloma. Phase 2 trials have reported that 25% of treated patients have renal adverse effects. Pre-renal/vasoconstriction-related insult from this chemotherapy agent has been documented. We describe a case of a 78-year-old man with refractory multiple myeloma with acute kidney injury associated with carfilzomib treatment. We show that use of N-acetyl-l-cysteine in our patient partially mitigated the renal injury upon re-challenge. This case report hypothesizes that acute renal injury from carfilzomib is caused by vasoconstriction of the renal vessels, which may be prevented by N-acetyl-l-cysteine.
Volume Number
21
Issue Number
4
Pages
313-6
Document Type
Article
EPub Date
2014/04/22
Status
Faculty
Facility
School of Medicine
Primary Department
Nephrology
Additional Departments
Hematology/Medical Oncology
PMID
DOI
10.1177/1078155214531804